UA34873A - Способ лечения хронического урогенитального хламидиоза - Google Patents
Способ лечения хронического урогенитального хламидиоза Download PDFInfo
- Publication number
- UA34873A UA34873A UA99074048A UA99074048A UA34873A UA 34873 A UA34873 A UA 34873A UA 99074048 A UA99074048 A UA 99074048A UA 99074048 A UA99074048 A UA 99074048A UA 34873 A UA34873 A UA 34873A
- Authority
- UA
- Ukraine
- Prior art keywords
- treatment
- patients
- chronic
- chlamydia
- course
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 56
- 230000001684 chronic effect Effects 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 20
- 108010047126 interferon-alpha 8 Proteins 0.000 claims abstract description 18
- 241000606161 Chlamydia Species 0.000 claims description 37
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 18
- 229940079322 interferon Drugs 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 229940124622 immune-modulator drug Drugs 0.000 claims description 2
- 238000011161 development Methods 0.000 abstract description 8
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 7
- 210000000987 immune system Anatomy 0.000 abstract description 4
- 206010003267 Arthritis reactive Diseases 0.000 abstract description 3
- 230000007969 cellular immunity Effects 0.000 abstract description 3
- 230000036512 infertility Effects 0.000 abstract description 3
- 208000002574 reactive arthritis Diseases 0.000 abstract description 3
- 238000012937 correction Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000000995 spontaneous abortion Diseases 0.000 abstract description 2
- 206010000234 Abortion spontaneous Diseases 0.000 abstract 1
- 208000015994 miscarriage Diseases 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 206010061041 Chlamydial infection Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 201000000902 chlamydia Diseases 0.000 description 6
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 229940065638 intron a Drugs 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000000686 immunotropic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 210000001539 phagocyte Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000606153 Chlamydia trachomatis Species 0.000 description 3
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229940038705 chlamydia trachomatis Drugs 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 2
- -1 7-IRN Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010059193 Acute hepatitis B Diseases 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010046482 Urethritis chlamydial Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 208000037628 acute hepatitis B virus infection Diseases 0.000 description 1
- 201000008346 acute salpingitis Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000403 immunocorrecting effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 230000004073 interleukin-2 production Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005617 polyoxidonium Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение, которое заявляется, касается медицины, точнее клинической иммунологии и предназначено для лечения хронического урогенитального хламидиоза, который протекает с определенными изменениями состояния иммунной системы. Задача, которая решается способом, который заявляется, заключается в коррекции иммунных нарушений клеточного иммунитета у больных хроническим урогенитальным хламидиозом иммуномодулирующими дозами Лаферона. Технический результат, который достигается, будет состоять в значительном уменьшении частоты хронизации урогенитального хламидиоза и предотвращении развития таких осложнений, как бесплодие, обычные выкидыши, реактивные артриты и др.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA99074048A UA34873A (ru) | 1999-07-14 | 1999-07-14 | Способ лечения хронического урогенитального хламидиоза |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA99074048A UA34873A (ru) | 1999-07-14 | 1999-07-14 | Способ лечения хронического урогенитального хламидиоза |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA34873A true UA34873A (ru) | 2001-03-15 |
Family
ID=74204218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99074048A UA34873A (ru) | 1999-07-14 | 1999-07-14 | Способ лечения хронического урогенитального хламидиоза |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA34873A (ru) |
-
1999
- 1999-07-14 UA UA99074048A patent/UA34873A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bowden et al. | Pilot study of azithromycin in the treatment of genital donovanosis. | |
| Lister et al. | Comparison of azithromycin and doxycycline in the treatment of non-gonococcal urethritis in men | |
| Simberkoff et al. | Mycoplasmemia in adult male patients | |
| RU2137483C1 (ru) | Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции | |
| UA34873A (ru) | Способ лечения хронического урогенитального хламидиоза | |
| Braff | Amoxicillin in the treatment of gonorrhea | |
| Feldblum et al. | Spermicide use and sexually transmitted disease | |
| RU2491956C2 (ru) | Способ лечения вагинальных инфекций | |
| RU2771856C1 (ru) | Способ лечения неосложненного некротизирующего энтероколита у новорожденных с бактериальной инфекцией и при подозрении на наличие внутриутробной инфекции | |
| RU2542377C1 (ru) | Способ лечения коклюша у детей в возрасте до трех лет | |
| RU2026681C1 (ru) | Способ формирования микрофлоры кишечника новорожденных при проведении предродовой подготовки матери | |
| RU2180569C2 (ru) | Способ лечения воспалительных заболеваний органов малого таза хламидийно-герпетической этиологии | |
| RU2146145C1 (ru) | Способ комплексной терапии больных хроническим аднекситом, рубцово-спаячным вариантом, неспецифической этиологии | |
| SU1715360A1 (ru) | Способ профилактики послеродовых инфекционных осложнений, вызванных граммотрицательными микроорганизмами | |
| Brewer et al. | Gonococcal arthritis in an adolescent girl | |
| RU2601408C1 (ru) | Способ лечения пациентов с лицевой болью с постгерпетическими ганглионитами головы | |
| RU2240824C1 (ru) | Способ лечения острого вирусного гепатита в | |
| SU1491516A1 (ru) | Способ лечени свежих острых и подострых неосложненных форм смешанной гонорейно-хламидийной инфекции мочеполовых органов | |
| RU2145891C1 (ru) | Способ комплексной терапии больных хроническим аднекситом, инфекционно-токсический вариант, неспецифической этиологии | |
| RU2154477C1 (ru) | Способ лечения хронического трихомониаза | |
| RU2163130C1 (ru) | Способ лечения хронического тонзиллита | |
| Naik et al. | Haematological profile in patients with Giardia lamblia infection | |
| RU2307656C1 (ru) | Способ лечения простатита хламидийной этиологии | |
| RU2193408C2 (ru) | Способ профилактики воспалительных осложнений после искусственного прерывания беременности в 1 триместре | |
| US20100004174A1 (en) | Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases |